VALBIOTIS announces a significant effect of VALEDIA® on intestinal microbiota

∙ VALEDIA® acts on microbiota imbalances associated with metabolic diseases (preclinical)

∙ In addition to the Phase I/II efficacy results in humans, this additional data strengthens the value of VALEDIA® for preventing type 2 diabetes

∙ VALBIOTIS continues its metagenomics program to assess how its products affect the microbiota

VALBIOTIS (FR0013254851 – ALVAL / PEA/SME eligible), a company that specializes in developing innovative nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients, announces that VALEDIA® has shown significant effects on the intestinal microbiota, in murine models of metabolic diseases. These results were selected for presentation at the Keystone “Bioenergetics and Metabolic Disease” symposium from 21 to 25 January 2018 in Keystone, Colorado (United States).

Stilla Technologies, Yuzi Holdings and TusPark donate digital PCR Naica™ Systems to help fight coronavirus outbreak in China
Bayer, Meiogenix collaborate to accelerate agricultural innovation through the development of unique technologies
Other news
Median Technologies records its best quarterly performance and joins forces with biopharmaceutical companies in the fight against Covid-19.
HORAMA Signs Exclusive License Agreement with Leiden University Medical Center Targeting CRB1 Gene Mutations to Treat Inherited Retinal Dystrophies
Hungary and the Netherlands approve Lipiodol® Ultra Fluid for hysterosalpingography in women undergoing infertility workup
Alexis RIDEAU appointed Chief Executive Officer of DEINOVE with the ambition to strengthen the Company’s strategy for innovation and partnerships